<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="572">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02484443</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2015-01001</org_study_id>
    <secondary_id>NCI-2015-01001</secondary_id>
    <secondary_id>AOST1421</secondary_id>
    <secondary_id>AOST1421</secondary_id>
    <secondary_id>AOST1421</secondary_id>
    <secondary_id>U10CA180886</secondary_id>
    <nct_id>NCT02484443</nct_id>
  </id_info>
  <brief_title>Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma</brief_title>
  <official_title>A Phase II Study of Human-Mouse Chimeric Anti-disialoganglioside Monoclonal Antibody Dinutuximab (ch14.18,NSC# 764038) in Combination With Sargramostim (GM-CSF) in Patients With Recurrent Osteosarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well dinutuximab works when given with sargramostim in
      treating patients with osteosarcoma that has come back after treatment (recurrent).
      Dinutuximab is a type of drug called a monoclonal antibody. It is designed to recognize a
      specific target on the surface of cancer cells. It then attaches to the cancer cells and
      kills them, without harming normal cells. Sargramostim may help the body increase the amount
      of white blood cells it produces, which help the body fight off infections. Giving
      sargramostim with dinutuximab may help the dinutuximab work better and kill more cancer
      cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the disease control rate in patients with completely resected recurrent
      osteosarcoma treated with ch14.18 (dinutuximab) in combination with sargramostim (GM-CSF) as
      compared to historical Children's Oncology Group (COG) experience.

      SECONDARY OBJECTIVES:

      I. To characterize the pharmacokinetics of ch14.18 (dinutuximab) in patients with recurrent
      osteosarcoma in the proposed administration schedule.

      II. To determine the occurrence of unacceptable toxicity (UT) in patients with recurrent
      osteosarcoma treated with ch14.18 (dinutuximab) in combination with sargramostim.

      TERTIARY OBJECTIVES:

      I. To assess the relationship between probability of disease control and tumor GD2
      expression.

      II. To assess killer cell immunoglobulin-like receptor (KIR) and Fcgamma receptor (FcgammaR)
      genotypes, natural killer cell p30 (NKp30) isoforms and its circulating ligand, B7-H6, and
      their relationships to the probability of disease control.

      III. To attempt banking of tumor samples for future research studies from patients enrolled
      on study who undergo biopsy or resection of suspected metastatic disease recurrence while on
      protocol therapy or during the evaluation period.

      IV. To determine a descriptive profile of human anti-chimeric antibody (HACA) during
      immunotherapy.

      OUTLINE:

      Patients receive sargramostim subcutaneously (SC) on days 1-14 and dinutuximab intravenously
      (IV) over 20 hours on days 4 and 5 (dinutuximab infusion may be extended for an additional 2
      days for anticipated toxicities). Treatment repeats every 28 days for up to 5 courses in the
      absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up periodically.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Disease control</measure>
    <time_frame>During the first 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The probability of remaining event-free as a function of time since enrollment will be estimated by the method of Kaplan and Meier. The complementary log-log transformation of the Kaplan-Meier estimate of the 12 month disease control probability will be used to construct confidence intervals of that probability. Only patients who can be confirmed to be free of detectable disease 12 months after enrollment, without intervening disease progression, will be considered to have experienced 12 month disease control.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of UT, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0</measure>
    <time_frame>Up to 4 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>A Bayesian rule will be used to monitor for excessive toxicity. Descriptive analyses of this safety information will be performed and will include the incidence of adverse events, severe adverse events, serious adverse events, and fatal adverse events. Type, frequency, and severity of laboratory abnormalities will also be analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of dinutuximab</measure>
    <time_frame>On days 4 and 5 of course 1 and then prior to the start of course 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>The average and standard deviation of estimates will be reported.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Banking of tumor samples (optional)</measure>
    <time_frame>During first 12 months from enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Individual statistical plans will be developed for future studies answering a specific question using these banked tumor specimens.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in circulating ligand B7-H6 levels</measure>
    <time_frame>Baseline to up to 4 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Additionally, serum for the evaluation of ligand levels at relapse will be requested. The change will be estimated by the average intra-patient change and the variance will be estimated by the variance of the intra-patient differences.</description>
  </other_outcome>
  <other_outcome>
    <measure>KIR, NKp30, and FcgammaR genotype analyses</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>The outcome measure will be DC success (yes versus no). Logistic regression using the categorical FcgammaR result will be fitted to the data. The fitted coefficients from the logistic regression, and the p-value for the test of the hypothesis of no relationship between FcgammaR result and probability of DC success will be used to characterize this exploratory analysis. Logistic regression using the categorical KIR/KIR ligand mismatch (present v. absent) will be fitted to the data.</description>
  </other_outcome>
  <other_outcome>
    <measure>Profile of HACA during immunotherapy</measure>
    <time_frame>Up to 30 days post-treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>At each time point, the optical density of the enzyme-linked immunosorbent assay (ELIZA) bridging assay will be calculated. The number of patients who are HACA positive divided by the number of patients with a successful HACA assay at each time point will be used to quantify the fraction of patients displaying HACA activity. Will also graph the average optical density of the ELIZA assay over all patients at each time point.</description>
  </other_outcome>
  <other_outcome>
    <measure>Tumor GD2 expression</measure>
    <time_frame>Up to 4 weeks post-treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>The relationship between probability of disease control (DC) and tumor GD2 expression will be assessed. The outcome measure will be DC success (yes versus no). Logistic regression using the categorical immunohistochemistry (IHC) result will be fitted to the data. The fitted coefficients from the logistic regression, and the p-value for the test of the hypothesis of no relationship between IHC result and probability of DC success will be used to characterize this exploratory analysis. Trend will also be assessed using the actual IHC numerical value.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Metastatic Malignant Neoplasm in the Lung</condition>
  <condition>Metastatic Osteosarcoma</condition>
  <condition>Recurrent Osteosarcoma</condition>
  <arm_group>
    <arm_group_label>Treatment (sargramostim and dinutuximab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive sargramostim SC on days 1-14 and dinutuximab IV over 20 hours on days 4 and 5 (dinutuximab infusion may be extended for an additional 2 days for anticipated toxicities). Treatment repeats every 28 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dinutuximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (sargramostim and dinutuximab)</arm_group_label>
    <other_name>Ch 14.18UTC</other_name>
    <other_name>Ch14.18</other_name>
    <other_name>MOAB Ch14.18</other_name>
    <other_name>monoclonal antibody Ch14.18</other_name>
    <other_name>Unituxin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (sargramostim and dinutuximab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (sargramostim and dinutuximab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sargramostim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (sargramostim and dinutuximab)</arm_group_label>
    <other_name>23-L-Leucinecolony-Stimulating Factor 2</other_name>
    <other_name>DRG-0012</other_name>
    <other_name>Leukine</other_name>
    <other_name>Prokine</other_name>
    <other_name>rhu GM-CFS</other_name>
    <other_name>Sagramostim</other_name>
    <other_name>Sargramostatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologic diagnosis of osteosarcoma at original diagnosis

          -  Patients must have had at least one episode of disease recurrence in the lungs
             without limitation on number of episodes of recurrence as long as they meet the
             following criteria:

               -  Surgical resection of all possible sites of suspected pulmonary metastases in
                  order to achieve a complete remission within 4 weeks prior to study enrollment**

               -  Pathologic confirmation of metastases from at least one of the resected sites

                    -  For patients with bilateral pulmonary metastases, resection must be
                       performed from both lungs and the study enrollment must be within 4 weeks
                       from date of the last lung surgery

               -  Note: If surgery related changes such as atelectasis are seen on the
                  post-operative computed tomography (CT) scan, patients will remain eligible to
                  enroll as long as the operating surgeon believes that all sites of metastases
                  were resected; patients with positive microscopic margins will be eligible to
                  enroll

          -  Patient must have adequate tumor specimen available for submission

          -  Patients must have a performance status corresponding to Eastern Cooperative Oncology
             Group (ECOG) scores of 0, 1 or 2; use Karnofsky for patients &gt; 16 years of age and
             Lansky for patients =&lt; 16 years of age

          -  Patients must have fully recovered from the acute toxic effects of all prior
             chemotherapy, immunotherapy, or radiotherapy prior to entering this study

               -  Myelosuppressive anti-cancer therapy: must not have been received within 2 weeks
                  of study entry (4 weeks if prior nitrosourea)

               -  Biologic (anti-neoplastic agent): at least 7 days since the completion of
                  therapy with a biologic agent

               -  Radiation therapy (RT): &gt;= 2 weeks for local palliative radiation therapy (RT)
                  (small port); &gt;= 6 weeks must have elapsed if prior craniospinal RT or if &gt;= 50%
                  radiation of pelvis; &gt;= 6 weeks must have elapsed if other substantial bone
                  marrow (BM) radiation

               -  Surgery: &gt;= 2 weeks from last major surgery, including pulmonary metastasectomy,
                  with the exclusion of a central line placement and core needle or small open
                  biopsies

          -  Patient must not have received pegfilgrastim (Neulasta) within 14 days of enrollment

          -  Patient must not have received filgrastim (G-CSF, Neupogen) within 7 days of
             enrollment

          -  Patient must not have received immune suppressants: corticosteroids (for other than
             allergic reactions and anaphylaxis), cyclosporine or tacrolimus within 7 days of
             enrollment

               -  Note: the use of topical and/or inhalational steroids is allowed

          -  Total absolute phagocyte count (APC = [%neutrophils + %monocytes) x white blood cells
             [WBC]) is at least 1000/uL

          -  Platelet count &gt;= 50,000/uL

          -  Creatinine clearance or radioisotope glomerular filtration rate (GFR) &gt;= 70
             mL/min/1.73 m^2 or

          -  A serum creatinine based on age/gender as follows:

               -  1 month to &lt; 6 months: 0.4 (male) 0.4 (female)

               -  6 months to &lt; 1 year: 0.5 (male), 0.5 (female)

               -  1 to &lt; 2 years: 0.6 (male), 0.6 (female)

               -  2 to &lt; 6 years: 0.8 (male), 0.8 (female)

               -  6 to &lt; 10 years: 1 (male), 1 (female)

               -  10 to &lt; 13 years: 1.2 (male), 1.2 (female)

               -  13 to &lt; 16 years: 1.5 (male), 1.4 (female)

               -  &gt;= 16 years: 1.7 (male), 1.4 (female)

          -  Total bilirubin =&lt; 1.5 x upper limit of normal (ULN) for age

          -  Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =&lt; 110
             U/L (for the purpose of this study, the ULN for SGPT is 45 U/L)

          -  Serum albumin &gt;= 2 g/dL

          -  Shortening fraction of &gt;= 27% by echocardiogram, or

          -  Ejection fraction of &gt;= 50% by radionuclide angiogram or echocardiogram

          -  No evidence of dyspnea at rest, no history of exercise intolerance, and a pulse
             oximetry &gt; 94%

          -  Patients with a known seizure disorder may be enrolled if on anticonvulsants and/or
             well controlled

          -  Central nervous system (CNS) toxicity including peripheral neuropathy =&lt; grade 2

        Exclusion Criteria:

          -  Patients with distant bone metastases at original diagnosis or relapse (patients with
             only skip lesions will be eligible)

          -  Patients with concurrent local and pulmonary recurrence at the time of enrollment;
             note: patients who had local recurrence previously that has been treated and now
             present with an isolated pulmonary recurrence and meet the surgical resection
             criteria stated above will be eligible

          -  Patients with primary refractory disease with progression of the primary tumor on
             initial therapy

          -  Patients with CNS disease or other sites of extra-pulmonary metastases at the time of
             most recent episode of disease recurrence preceding enrollment

          -  Patients with a prior hypersensitivity reaction to sargramostim

          -  Patients who have received prior anti-GD2 therapy, including chimeric antigen
             receptor (CAR) T cells directed against GD2 antigen

          -  Female patients who are pregnant are ineligible

          -  Lactating females are not eligible unless they have agreed not to breastfeed their
             infants

          -  Female patients of childbearing potential are not eligible unless a negative
             pregnancy test result has been obtained

          -  Sexually active patients of reproductive potential are not eligible unless they have
             agreed to use an effective contraceptive method for the duration of their study
             participation; patients should maintain adequate contraception for a minimum of 2
             months after the last dose of ch14.18 (dinutuximab)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>29 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pooja Hingorani</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alyssa T. Reddy</last_name>
      <phone>205-975-1941</phone>
      <email>areddy@peds.uab.edu</email>
    </contact>
    <investigator>
      <last_name>Alyssa T. Reddy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Phoenix Childrens Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Boklan</last_name>
      <phone>602-933-0276</phone>
      <email>jboklan@phoenixchildrens.com</email>
    </contact>
    <investigator>
      <last_name>Jessica Boklan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202-3591</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David L. Becton</last_name>
      <phone>501-364-7373</phone>
      <email>bectondavidl@uams.edu</email>
    </contact>
    <investigator>
      <last_name>David L. Becton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern California Permanente Medical Group</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert M. Cooper</last_name>
      <phone>626-564-3455</phone>
      <email>robert.m.cooper@kp.org</email>
    </contact>
    <investigator>
      <last_name>Robert M. Cooper</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert Kheradpour</last_name>
      <phone>909-558-0702</phone>
      <email>akheradp@llu.edu</email>
    </contact>
    <investigator>
      <last_name>Albert Kheradpour</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leo Mascarenhas</last_name>
      <phone>323-361-8174</phone>
      <email>lmascarenhas@chla.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Leo Mascarenhas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Violet Shen</last_name>
      <phone>714-509-8699</phone>
      <email>vshen@choc.org</email>
    </contact>
    <investigator>
      <last_name>Violet Shen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neyssa M. Marina</last_name>
      <phone>650-723-5231</phone>
      <email>clinicaltrials@med.stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Neyssa M. Marina</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcio H. Malogolowkin</last_name>
      <phone>916-734-3089</phone>
    </contact>
    <investigator>
      <last_name>Marcio H. Malogolowkin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center-Mission Bay</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert E. Goldsby</last_name>
      <phone>877-827-3222</phone>
      <email>goldsbyr@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Robert E. Goldsby</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy P. Garrington</last_name>
      <phone>720-777-7279</phone>
      <email>timothy.garrington@childrenscolorado.org</email>
    </contact>
    <investigator>
      <last_name>Timothy P. Garrington</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer J. Clark</last_name>
      <phone>303-832-3721</phone>
      <email>jennifer.clark5@hcahealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Jennifer J. Clark</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Medical Center</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael S. Isakoff</last_name>
      <phone>860-545-9981</phone>
      <email>misakoff@connecticutchildrens.org</email>
    </contact>
    <investigator>
      <last_name>Michael S. Isakoff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina S. Kadan-Lottick</last_name>
      <phone>203-785-5702</phone>
      <email>nina.kadan-lottick@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Nina S. Kadan-Lottick</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alfred I duPont Hospital for Children</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott M. Bradfield</last_name>
      <phone>904-697-3792</phone>
      <email>sbradfie@nemours.org</email>
    </contact>
    <investigator>
      <last_name>Scott M. Bradfield</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William B. Slayton</last_name>
      <phone>352-392-8725</phone>
      <email>trials@cancer.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>William B. Slayton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic-Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott M. Bradfield</last_name>
      <phone>904-697-3792</phone>
      <email>sbradfie@nemours.org</email>
    </contact>
    <investigator>
      <last_name>Scott M. Bradfield</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nicklaus Children's Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrique A. Escalon</last_name>
      <phone>888-624-2778</phone>
      <email>enrique.escalon@mch.com</email>
    </contact>
    <investigator>
      <last_name>Enrique A. Escalon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arnold Palmer Hospital for Children</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent F. Giusti</last_name>
      <phone>321-841-7743</phone>
      <email>vincent.giusti@orlandohealth.com</email>
    </contact>
    <investigator>
      <last_name>Vincent F. Giusti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott M. Bradfield</last_name>
      <phone>904-697-3792</phone>
      <email>sbradfie@nemours.org</email>
    </contact>
    <investigator>
      <last_name>Scott M. Bradfield</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic - Pensacola</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott M. Bradfield</last_name>
      <phone>904-697-3792</phone>
      <email>sbradfie@nemours.org</email>
    </contact>
    <investigator>
      <last_name>Scott M. Bradfield</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>All Children's Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory A. Hale</last_name>
      <phone>727-767-4379</phone>
      <email>HamblinF@allkids.org</email>
    </contact>
    <investigator>
      <last_name>Gregory A. Hale</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph's Hospital/Children's Hospital-Tampa</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark J. Mogul</last_name>
      <phone>813-287-6306</phone>
      <email>mark.mogul@baycare.org</email>
    </contact>
    <investigator>
      <last_name>Mark J. Mogul</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Mary's Hospital</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Narayana Gowda</last_name>
      <phone>888-823-5923</phone>
      <email>ctsucontact@westat.com</email>
    </contact>
    <investigator>
      <last_name>Narayana Gowda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta - Egleston</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William T. Cash</last_name>
      <phone>404-727-4455</phone>
      <email>thomas.cash@choa.org</email>
    </contact>
    <investigator>
      <last_name>William T. Cash</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial University Medical Center</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J. M. Johnston</last_name>
      <phone>912-350-8568</phone>
    </contact>
    <investigator>
      <last_name>J. M. Johnston</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kapiolani Medical Center for Women and Children</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96826</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wade T. Kyono</last_name>
      <phone>808-983-8005</phone>
      <email>kyono@hawaii.edu</email>
    </contact>
    <investigator>
      <last_name>Wade T. Kyono</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Mountain States Tumor Institute</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugenia Chang</last_name>
      <phone>208-381-2974</phone>
      <email>change@slhs.org</email>
    </contact>
    <investigator>
      <last_name>Eugenia Chang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lurie Children's Hospital-Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David O. Walterhouse</last_name>
      <phone>312-227-9376</phone>
      <email>d-walterhouse@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>David O. Walterhouse</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan L. Cohn</last_name>
      <phone>773-834-1329</phone>
      <email>scohn@peds.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Susan L. Cohn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Jude Midwest Affiliate</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen S. Fernandez</last_name>
      <phone>309-624-9848</phone>
      <email>kfernand@uic.edu</email>
    </contact>
    <investigator>
      <last_name>Karen S. Fernandez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert J. Fallon</last_name>
      <phone>317-948-0616</phone>
      <email>rfallon@iupui.edu</email>
    </contact>
    <investigator>
      <last_name>Robert J. Fallon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Hospital and Health Care Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bassem I. Razzouk</last_name>
      <phone>317-338-3227</phone>
      <email>research@stvincent.org</email>
    </contact>
    <investigator>
      <last_name>Bassem I. Razzouk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Blank Children's Hospital</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy L. Woods-Swafford</last_name>
      <phone>515-241-8988</phone>
      <email>wendy.woods-swafford@unitypoint.org</email>
    </contact>
    <investigator>
      <last_name>Wendy L. Woods-Swafford</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa/Holden Comprehensive Cancer Center</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariko Sato</last_name>
      <phone>319-356-7659</phone>
      <email>mariko-sato@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Mariko Sato</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky/Markey Cancer Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars M. Wagner</last_name>
      <phone>859-257-6048</phone>
      <email>lars.wagner@uky.edu</email>
    </contact>
    <investigator>
      <last_name>Lars M. Wagner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center Jefferson</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig Lotterman</last_name>
      <phone>504-842-5250</phone>
      <email>clotterman@ochsner.org</email>
    </contact>
    <investigator>
      <last_name>Craig Lotterman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eastern Maine Medical Center</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sam W. Lew</last_name>
      <phone>800-987-3005</phone>
      <email>slew@emhs.org</email>
    </contact>
    <investigator>
      <last_name>Sam W. Lew</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sinai Hospital of Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph M. Wiley</last_name>
      <phone>410-601-8766</phone>
      <email>pridgely@lifebridgehealth.org</email>
    </contact>
    <investigator>
      <last_name>Joseph M. Wiley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University/Sidney Kimmel Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David M. Loeb</last_name>
      <phone>410-955-8804</phone>
      <email>jhcccro@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>David M. Loeb</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine A. Janeway</last_name>
      <phone>877-442-3324</phone>
    </contact>
    <investigator>
      <last_name>Katherine A. Janeway</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine A. Janeway</last_name>
      <phone>877-442-3324</phone>
    </contact>
    <investigator>
      <last_name>Katherine A. Janeway</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>C S Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rama Jasty</last_name>
      <phone>800-865-1125</phone>
      <email>rjasty@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Rama Jasty</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint John Hospital and Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hadi Sawaf</last_name>
      <phone>313-343-3166</phone>
    </contact>
    <investigator>
      <last_name>Hadi Sawaf</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helen DeVos Children's Hospital at Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen J. Yost</last_name>
      <phone>616-391-1230</phone>
      <email>connie.szczepanek@grcop.org</email>
    </contact>
    <investigator>
      <last_name>Kathleen J. Yost</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bronson Methodist Hospital</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen J. Yost</last_name>
      <phone>616-391-1230</phone>
      <email>connie.szczepanek@grcop.org</email>
    </contact>
    <investigator>
      <last_name>Kathleen J. Yost</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospitals and Clinics of Minnesota - Minneapolis</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael K. Richards</last_name>
      <phone>612-813-6325</phone>
      <email>michael.richards@childrensmn.org</email>
    </contact>
    <investigator>
      <last_name>Michael K. Richards</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota/Masonic Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily G. Greengard</last_name>
      <phone>612-624-2620</phone>
      <email>emilyg@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Emily G. Greengard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anderson (Andy) B. Collier</last_name>
      <phone>601-984-5279</phone>
      <email>acollier@umc.edu</email>
    </contact>
    <investigator>
      <last_name>Anderson (Andy) B. Collier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Childrens Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maxine L. Hetherington</last_name>
      <phone>816-302-9894</phone>
      <email>mhetherington@cmh.edu</email>
    </contact>
    <investigator>
      <last_name>Maxine L. Hetherington</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardinal Glennon Children's Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William S. Ferguson</last_name>
      <phone>314-268-4000</phone>
      <email>fergusws@slu.edu</email>
    </contact>
    <investigator>
      <last_name>William S. Ferguson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederick S. Huang</last_name>
      <phone>800-600-3606</phone>
      <email>info@siteman.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Frederick S. Huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital Saint Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bethany G. Sleckman</last_name>
      <phone>913-948-5588</phone>
    </contact>
    <investigator>
      <last_name>Bethany G. Sleckman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Medical Center of Omaha</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minnie Abromowitch</last_name>
      <phone>402-955-3972</phone>
      <email>mabromowitch@childrensomaha.org</email>
    </contact>
    <investigator>
      <last_name>Minnie Abromowitch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minnie Abromowitch</last_name>
      <phone>402-955-3972</phone>
      <email>mabromowitch@childrensomaha.org</email>
    </contact>
    <investigator>
      <last_name>Minnie Abromowitch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Specialty Center of Nevada II</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan K. Ikeda</last_name>
      <phone>702-732-1080</phone>
      <email>aikeda@cure4thekids.org</email>
    </contact>
    <investigator>
      <last_name>Alan K. Ikeda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunrise Hospital and Medical Center</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan K. Ikeda</last_name>
      <phone>702-732-1080</phone>
      <email>aikeda@cure4thekids.org</email>
    </contact>
    <investigator>
      <last_name>Alan K. Ikeda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Summerlin Hospital Medical Center</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan K. Ikeda</last_name>
      <phone>702-732-1080</phone>
      <email>aikeda@cure4thekids.org</email>
    </contact>
    <investigator>
      <last_name>Alan K. Ikeda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael B. Harris</last_name>
      <phone>201-996-2879</phone>
      <email>mbharris@hackensackumc.org</email>
    </contact>
    <investigator>
      <last_name>Michael B. Harris</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vikramjit S. Kanwar</last_name>
      <phone>518-262-3368</phone>
      <email>kanwarv@mail.amc.edu</email>
    </contact>
    <investigator>
      <last_name>Vikramjit S. Kanwar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center - Moses Campus</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467-2490</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan B. Gill</last_name>
      <phone>718-904-2730</phone>
      <email>aecc@aecom.yu.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan B. Gill</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University/Herbert Irving Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice Lee</last_name>
      <phone>212-305-5848</phone>
      <email>al2041@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Alice Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>State University of New York Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karol H. Kerr</last_name>
      <phone>315-464-7238</phone>
      <email>kerrk@upstate.edu</email>
    </contact>
    <investigator>
      <last_name>Karol H. Kerr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford Medical Center-Fargo</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel O. Anim</last_name>
      <phone>701-234-7577</phone>
      <email>samuel.anim@sanfordhealth.org</email>
    </contact>
    <investigator>
      <last_name>Samuel O. Anim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Medical Center of Akron</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven J. Kuerbitz</last_name>
      <phone>330-543-3220</phone>
      <email>skuerbitz@chmca.org</email>
    </contact>
    <investigator>
      <last_name>Steven J. Kuerbitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph G. Pressey</last_name>
      <phone>513-636-2799</phone>
      <email>joseph.pressey@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Joseph G. Pressey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies and Childrens Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yousif (Joe) H. Matloub</last_name>
      <phone>216-844-5431</phone>
      <email>yousif.matloub@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Yousif (Joe) H. Matloub</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark A. Ranalli</last_name>
      <phone>614-722-3699</phone>
      <email>mark.ranalli@nationwidechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Mark A. Ranalli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dayton Children's Hospital</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ayman A. El-Sheikh</last_name>
      <phone>937-641-3296</phone>
      <email>elsheikha@childrensdayton.org</email>
    </contact>
    <investigator>
      <last_name>Ayman A. El-Sheikh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Toledo Hospital/Toledo Children's Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie L. Dargart</last_name>
      <phone>419-824-1842</phone>
    </contact>
    <investigator>
      <last_name>Jamie L. Dargart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rene Y. McNall-Knapp</last_name>
      <phone>405-271-8777</phone>
      <email>ou-clinical-trials@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Rene Y. McNall-Knapp</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suman Malempati</last_name>
      <phone>503-494-0714</phone>
      <email>trials@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Suman Malempati</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard B. Womer</last_name>
      <phone>215-590-4183</phone>
      <email>rwomer@mail.med.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Richard B. Womer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Childrens Oncology Group</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pooja Hingorani</last_name>
      <phone>602-933-0920</phone>
      <email>phingorani@phoenixchildrens.com</email>
    </contact>
    <investigator>
      <last_name>Pooja Hingorani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean M. Tersak</last_name>
      <phone>412-692-7693</phone>
      <email>jean.tersak@chp.edu</email>
    </contact>
    <investigator>
      <last_name>Jean M. Tersak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BI-LO Charities Children's Cancer Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nichole L. Bryant</last_name>
      <phone>864-455-5164</phone>
      <email>nbryant@ghs.org</email>
    </contact>
    <investigator>
      <last_name>Nichole L. Bryant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford USD Medical Center - Sioux Falls</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57117-5134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kayelyn J. Wagner</last_name>
      <phone>605-328-1367</phone>
    </contact>
    <investigator>
      <last_name>Kayelyn J. Wagner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael W. Bishop</last_name>
      <phone>901-521-9005</phone>
      <email>info@stjude.org</email>
    </contact>
    <investigator>
      <last_name>Michael W. Bishop</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dell Children's Medical Center of Central Texas</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy C. Fowler</last_name>
      <phone>512-628-1901</phone>
      <email>acFowler@seton.org</email>
    </contact>
    <investigator>
      <last_name>Amy C. Fowler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical City Dallas Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stanton C. Goldman</last_name>
      <phone>972-566-6496</phone>
      <email>stan.goldman@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Stanton C. Goldman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern/Simmons Cancer Center-Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theodore W. Laetsch</last_name>
      <phone>214-648-7097</phone>
    </contact>
    <investigator>
      <last_name>Theodore W. Laetsch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren J. Akers</last_name>
      <phone>682-885-1713</phone>
      <email>lauren.akers@cookchildrens.org</email>
    </contact>
    <investigator>
      <last_name>Lauren J. Akers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo J. Flores</last_name>
      <phone>832-825-4846</phone>
      <email>burton@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Ricardo J. Flores</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy C. Griffin</last_name>
      <phone>713-798-1354</phone>
      <email>burton@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Timothy C. Griffin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Marie R. Langevin</last_name>
      <phone>210-702-6014</phone>
      <email>CTO@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Anne-Marie R. Langevin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phillip E. Barnette</last_name>
      <phone>801-662-4707</phone>
      <email>phillip.barnette@imail.org</email>
    </contact>
    <investigator>
      <last_name>Phillip E. Barnette</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital-King's Daughters</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric J. Lowe</last_name>
      <phone>757-668-7243</phone>
      <email>eric.lowe@chkd.org</email>
    </contact>
    <investigator>
      <last_name>Eric J. Lowe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas S. Hawkins</last_name>
      <phone>206-987-3946</phone>
      <email>doug.hawkins@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Douglas S. Hawkins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Sacred Heart Medical Center and Children's Hospital</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judy L. Felgenhauer</last_name>
      <phone>509-474-6222</phone>
      <email>HopeBeginsHere@providence.org</email>
    </contact>
    <investigator>
      <last_name>Judy L. Felgenhauer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Virginia University Healthcare</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan R. Paul</last_name>
      <phone>304-293-1216</phone>
      <email>sfilburn@hsc.wvu.edu</email>
    </contact>
    <investigator>
      <last_name>Stephan R. Paul</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Midwest Children's Cancer Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul D. Harker-Murray</last_name>
      <phone>414-805-4380</phone>
      <email>pharker@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Paul D. Harker-Murray</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Hunter Children's Hospital</name>
      <address>
        <city>Hunter Regional Mail Centre</city>
        <state>New South Wales</state>
        <zip>2310</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geoffrey B. McCowage</last_name>
      <phone>61-2-9845-2171</phone>
      <email>geoff.mccowage@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Geoffrey B. McCowage</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sydney Children's Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geoffrey B. McCowage</last_name>
      <phone>61-2-9845-2171</phone>
      <email>geoff.mccowage@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Geoffrey B. McCowage</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital at Westmead</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geoffrey B. McCowage</last_name>
      <phone>61-2-9845-2171</phone>
      <email>geoff.mccowage@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Geoffrey B. McCowage</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lady Cilento Children's Hospital</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geoffrey B. McCowage</last_name>
      <phone>61-2-9845-2171</phone>
      <email>geoff.mccowage@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Geoffrey B. McCowage</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women's and Children's Hospital-Adelaide</name>
      <address>
        <city>North Adelaide</city>
        <state>South Australia</state>
        <zip>5006</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria L. Kirby</last_name>
      <phone>08-8161-7327</phone>
      <email>cywhs.oncsec@health.sa.gov.au</email>
    </contact>
    <investigator>
      <last_name>Maria L. Kirby</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monash Medical Center-Clayton Campus</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geoffrey B. McCowage</last_name>
      <phone>61-2-9845-2171</phone>
      <email>geoff.mccowage@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Geoffrey B. McCowage</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IWK Health Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Conrad V. Fernandez</last_name>
      <phone>902-470-8394</phone>
      <email>conrad.fernandez@iwk.nshealth.ca</email>
    </contact>
    <investigator>
      <last_name>Conrad V. Fernandez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Pediatric Hospital</name>
      <address>
        <city>San Juan</city>
        <zip>00926</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis A. Clavell</last_name>
      <phone>787-727-1000</phone>
      <email>luisclavell@sjcms.com</email>
    </contact>
    <investigator>
      <last_name>Luis A. Clavell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>June 15, 2016</lastchanged_date>
  <firstreceived_date>June 26, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Osteosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
